Stereotactic ablative radiotherapy for early stage non-small cell lung cancer: A critical literature review of predictive factors of relapse-Reference-Cited by-同舟云学术

Stereotactic ablative radiotherapy for early stage non-small cell lung cancer: A critical literature review of predictive factors of relapse

Published:2016-11 Issue: Volume:50 Page:240-246
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Loganadane Gokoulakrichenane,Martinetti Florent,Mercier Olaf,Krhili Samar,Riet François-Georges,Mbagui Rodrigue,To Hanh,Le Péchoux Cécile,Levy Antonin

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Reference69 articles.

1. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group;Ginsberg;Ann Thorac Surg,1995

2. Stereotactic ablative radiation therapy for the treatment of early-stage non-small-cell lung cancer: CEPO review and recommendations;Boily;J Thorac Oncol Off Publ Int Assoc StudyLung Cancer,2015

3. 2nd ESMO consensus conference on lung cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up;Vansteenkiste;Ann Oncol Off J Eur Soc Med Oncol ESMO,2014

4. The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered to be at higher risk of complications from surgical resection

5. JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for lung cancer – full text view – clinicaltrials.gov. Available at: ; [accessed august 14, 2016].

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stereotactic body radiotherapy in lung cancer: a contemporary review;Pathology and Oncology Research;2024-02-27

2. Reirradiation with stereotactic body radiotherapy for primary or secondary lung malignancies: Tumor control probability and safety analyses;Radiotherapy and Oncology;2023-10

3. Real-World Results of Stereotactic Body Radiotherapy for 399 Medically Operable Patients with Stage I Histology-Proven Non-Small Cell Lung Cancer;Cancers;2023-09-01

4. Predicting cancer relapse following lung stereotactic radiotherapy: an external validation study using real-world evidence;Frontiers in Oncology;2023-07-12

5. Gut Microbiome Is Associated With the Response to Chemoradiotherapy in Patients With Non-small Cell Lung Cancer;International Journal of Radiation Oncology*Biology*Physics;2023-02